Search

Search Constraints

You searched for: Author/Creator Aghemo, A.

Search Results

1. A multicentre prospective study response to treatment in genotype 3 and 1b infected patients with sickest liver cirrhosis: SVR 4 is not a reliable measure. (8th October 2016)

2. Changes of AFP and PIVKA-II levels during DAA treatment and their predictive value for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment. Issue 1 (February 2018)

3. Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN. Issue 1 (16th February 2017)

6. Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network. Issue 1 (February 2018)

7. Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks. (February 2019)

8. Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients. (February 2019)

10. Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group. Issue 1 (February 2018)